亚宝药业：终止SY-009临床试验并计提5579.33万元资产减值准备

Core Viewpoint - The company has decided to terminate the clinical research and development of SY-009 capsules, leading to a full impairment of the capitalized R&D amount of 55.7933 million yuan, which will reduce the company's total profit for 2025 by the same amount [1] Group 1: Project Termination - The company announced the termination of the clinical research for SY-009 capsules [1] - SY-009 is a sodium-glucose co-transporter 1 inhibitor aimed at reducing postprandial glucose absorption for the treatment of type 2 diabetes [1] Group 2: Financial Impact - The impairment of the R&D capitalized amount of 55.7933 million yuan will directly impact the company's profit for the year 2025 [1] Group 3: Clinical Trial Results - Phase II clinical trial results indicated a relationship between dosage and efficacy, but the primary efficacy endpoint was not met [1] - The company faces significant uncertainty regarding further R&D investments and the time required to conduct additional trials [1]